Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Year founded2012
Served areaWorldwide
HeadquartersChemin des Aulx 12, 1228 Plan-les-Ouates – Switzerland
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
17.03.22 | None | Non-Executive member | Buy | CHF 2,058.00 |
16.03.22 | None | Non-Executive member | Buy | CHF 27,010.00 |
15.03.22 | None | Non-Executive member | Buy | CHF 23,642.00 |
08.02.22 | None | Non-Executive member | Buy | CHF 64,161.00 |
01.02.22 | None | Non-Executive member | Buy | CHF 70,716.00 |
24.01.22 | None | Non-Executive member | Buy | CHF 69,748.00 |
11.01.22 | None | Non-Executive member | Buy | CHF 183,535.00 |
10.01.22 | None | Non-Executive member | Buy | CHF 177,643.00 |
CH0346177709
LEI549300PNZ0UEJVKN1618
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.